Suven Life Sciences (Suven) is participating and presenting positive Pre-clinical and Phase-1 clinical data of several advanced molecules from their portfolio of new chemical entities (NCEs) and the status of Phase 2 clinical trial of their lead compound SUVN-502 at Neuroscience 2018, organized by Society for Neuroscience being held at San Diego, USA during November 4-7, 2018. Neuroscience is the annual meeting of the Society for Neuroscience (SFN) and more than 30 thousand Neuro-Scientists from all over the world covering the major Pharma, Biotech and Clinical Research institutes will be participating at this conference.
Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies using GPCR targets.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1842.30 |
| Dr. Reddys Lab | 1278.10 |
| Cipla | 1336.80 |
| Zydus Lifesciences | 932.30 |
| Lupin | 2273.05 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: